SynthesisFuture oncology (London, England)2025
Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.
Synthesis in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial lung disease (ILD) can occur in patients with cancer. ILD can be caused by anti-cancer treatments (drug-induced [DI] ILD), but also by opportunistic infection, and non-drug-related etiologies. This systematic literature review (SLR) investigated the epidemiology and etiology of non-DI ILD and DI ILD management and outcomes in patients with solid cancers.
methodsDatabases were searched to August 2023 using terms for ILD and solid cancers. Relevant congresses held 2021-2023 and SLR bibliographies were hand-searched. Records were screened by two independent reviewers. Inclusion criteria comprised ILD epidemiology outcomes, ILD clinical management, and survival outcomes.
resultsOf 4,519 unique records screened, 55 full texts were included (six from supplementary sources) and 37 were prioritized for extraction. Studies were frequently retrospective cohort studies in Japan (n = 21). Patients mostly had lung cancers (n = 32) and received immune checkpoint inhibitors (n = 24). Reporting of non-DI ILD was limited and associated with radiation therapy (n = 4) or surgery (n = 1). Most studies reported DI ILD outcomes only (n = 31).
conclusionThe limited evidence of non-DI ILD indicates that prompt intervention to manage ILD until other ILD etiologies have been ruled out remains key to preventing progression of both cancer and ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.